HomepageSHPHF • OTCMKTS
add
Sihuan Pharmaceutical Holdings Group Ltd
Vorige slotkoers
$ 0,049
Jaar-range
$ 0,045 - $ 0,095
Beurswaarde
5,68 mld. HKD
Koers/winst
-
Dividendrendement
-
Primaire beurs
HKG
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(CNY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 474,85 mln. | -10,04% |
Bedrijfskosten | 301,93 mln. | -12,13% |
Netto inkomsten | -16,71 mln. | 32,67% |
Netto winstmarge | -3,52 | 25,11% |
Winst per aandeel | — | — |
EBITDA | 56,91 mln. | -32,62% |
Effectief belastingtarief | -253,73% | — |
Balans
Totale activa
Totale passiva
(CNY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 4,86 mld. | 7,86% |
Totale activa | 11,53 mld. | -2,11% |
Totale passiva | 6,44 mld. | -1,32% |
Totaal aandelenvermogen | 5,09 mld. | — |
Uitstaande aandelen | 9,32 mld. | — |
Koers-boekwaardeverhouding | 0,10 | — |
Rendement op activa | 0,05% | — |
Rendement op kapitaal | 0,09% | — |
Kasstroom
Nettomutatie in liquide middelen
(CNY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -16,71 mln. | 32,67% |
Operationele kasstroom | 18,23 mln. | 28,75% |
Kasstroom uit beleggingen | 126,63 mln. | 152,35% |
Kasstroom uit financiering | -29,16 mln. | 73,91% |
Nettomutatie in liquide middelen | 115,70 mln. | 344,01% |
Vrije kasstroom | -12,85 mln. | -53,24% |
Over
Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province. The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market.
Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease. The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan. Wikipedia
CEO
Opgericht
2001
Website
Werknemers
2.648